Malaysia

Malaysia operates a dual regulatory framework for health products. Medical devices are regulated by the Medical Device Authority (MDA) under the Medical Device Act 2012 (Act 737), which requires all medical devices to be registered in the Malaysian Medical Device Register (MeDC@St) before they can be placed on the market. Pharmaceuticals, diagnostics classified as in-vitro diagnostics under pharmaceutical definitions, and related biological products fall under the purview of the National Pharmaceutical Regulatory Agency (NPRA), governed by the Control of Drugs and Cosmetics Regulations 1984 under the Sale of Drugs Act 1952. Both agencies operate under the Ministry of Health Malaysia (MOH) and employ a risk-based classification system to determine the level of scrutiny applied during product evaluation. Digital health solutions and software as a medical device (SaMD) are increasingly subject to MDA oversight, with guidance aligned to international frameworks such as those from the International Medical Device Regulators Forum (IMDRF).

For medical devices, applicants must appoint a locally registered Authorized Representative (AR) if the manufacturer is based outside Malaysia, and submissions are made through the MeDC@St online portal. Device classification follows a Class A through D risk stratification, with Class A self-declared and Classes B, C, and D subject to conformity assessment. For pharmaceuticals, submissions follow the ACTD (ASEAN Common Technical Dossier) format, consistent with ASEAN harmonization commitments, though CTD-formatted dossiers are also accepted. Malaysia is an active participant in the ASEAN Medical Device Directive (AMDD) harmonization initiative and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), and the NPRA has implemented mutual recognition pathways and expedited review tracks for products already approved by reference agencies such as the US FDA, EMA, TGA, or Health Canada. Recent reforms include the full enforcement of the Medical Device Act for all device classes, expansion of digital submission platforms, and growing alignment with post-market surveillance requirements.

Public sector procurement in Malaysia is centralized primarily through the Ministry of Health Malaysia, which manages procurement for government hospitals, clinics, and health facilities nationwide. Large-scale and high-value health product tenders are coordinated through the MOH Procurement Division and the Ministry of Finance (MOF), with the latter overseeing government-wide procurement policy under the Financial Procedure Act 1957 and Treasury Instructions. National-level tenders for pharmaceuticals and medical devices are often managed via standing agreements and panel contracts, with the Pharmacy Services Programme (PSP) playing a central role in pharmaceutical procurement for public facilities. The Materials Management Unit (UPB) and relevant technical divisions within MOH assess and shortlist suppliers, and registration in both the MOH supplier database and the Ministry of Finance vendor system (ePerolehan) is generally required to participate in public tenders. State health departments may conduct their own procurement for certain consumables and locally sourced items, but strategic and high-value products are typically procured at the federal level.

The private healthcare sector in Malaysia is substantial and independently procures products through hospital group purchasing organizations, private distributors, and direct manufacturer agreements, with pricing negotiated commercially rather than through government tender processes. Major private hospital groups such as IHH Healthcare and KPJ Healthcare exercise significant purchasing influence in this channel. Malaysia does not rely heavily on donor-funded procurement mechanisms such as UNICEF Supply Division, the Global Fund, or USAID for mainstream health products, given its upper-middle-income status; however, targeted programs for communicable disease control may involve international agency coordination. The government has articulated policies to encourage local manufacturing and domestic industry development, including preferences for locally manufactured products in certain procurement categories and incentives under the National Pharmaceutical Industry Blueprint. Companies with local manufacturing or technology transfer arrangements may benefit from preferential positioning in public tenders, and the government actively promotes Malaysia as a regional pharmaceutical manufacturing hub under broader industrial policy frameworks.